文献速递妇科

BRCA突变女性卵巢癌监测:ROCA算法与标准超声联合CA125的比较

Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
PubMed 文献 · Gynecol Oncol · 2020-03-04

该非随机前瞻性队列研究纳入BRCA突变女性,比较每4个月检测CA125和HE4的ROCA监测方案与每6个月CA125联合盆腔超声的标准监测。ROCA组依从性更高(83.2% vs 51.9%,p<0.0001),12个月时回避感受显著减轻(20.8% vs 9.9%严重,p=0.034),侵入感接近显著(7.6% vs 4.1%严重,p=0.057)。

要点

  • ROCA组每4个月血检依从性83.2%,显著高于标准监测组的51.9%。
  • ROCA组12个月时回避感受严重比例9.9%,显著低于基线的20.8%。
  • 传统超声联合CA125监测临床效用不足且依从性差。

核心结论

  • 每4个月进行ROCA生物标志物监测的依从性高,且ROCA组女性随时间推移压力评分低于标准监测组。
  • 鉴于传统超声和CA125检测缺乏临床效用且依从性差,有必要进一步研究纵向生物标志物监测用于卵巢癌早期检测。

研究设计与样本

  • ROCA组159人接受每4个月血清CA125和HE4检测,标准监测组43人接受每6个月CA125和盆腔超声。

主要发现

  • ROCA组总体依从性83.2%,标准监测组51.9%,p<0.0001。
  • 基于IES量表,ROCA组12个月时侵入感严重比例7.6% vs 基线4.1%,p=0.057,接近显著。
  • ROCA组12个月时回避感受严重比例9.9% vs 基线20.8%,p=0.034,差异显著。

临床怎么用

  • 对于BRCA突变女性,每4个月血清CA125和HE4的ROCA监测方案依从性高且可能减轻心理压力,但需进一步验证。
  • 传统每6个月CA125联合盆腔超声监测依从性较低,临床效用不足。

局限性

  • 研究为非随机设计,样本量有限(ROCA组159人,标准监测组43人)。
  • 部分心理指标差异仅接近显著(侵入感p=0.057)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed the feasibility, patient acceptability of and compliance of a new surveillance strategy for ovarian cancer surveillance in women with BRCA mutations, based on assessments of serum CA125 and HE4 every 4 months (Risk of Ovarian Cancer Algorithm (ROCA) arm), compared to Standard of Care (SOC) surveillance with CA125 blood tests and pelvic ultrasounds every 6 months. METHODS: Women were recruited 6/13/16-9/11/17 from an integrated health care system in California for this non-randomized prospective cohort study. Women were invited to participate in a novel serum biomarker surveillance strategy using ROCA or they could opt to be in the standard of care control arm with ultrasound and CA 125 every 6 months. Outcomes assessed included compliance, self-reported distress using the Impact of Event Scale (IES) and cancer anxiety using the Cancer Worry Scale. RESULTS: There were 159 women in the ROCA arm and 43 in the SOC arm. Overall, compliance was higher in the ROCA arm (83.2%) than in SOC (51.9%), p < 0.0001. Based on the IES, ROCA arm women reported less feelings about intrusion and avoidance at 12 months compared to baseline; the difference approached significance for intrusion (7.6% vs 4.1% severe, p = 0.057) and was statistically significant for avoidance (20.8% vs 9.9% severe, p = 0.034). CONCLUSIONS: This pilot demonstrated that compliance was high with blood tests performed every four months for ovarian cancer surveillance. Moreover, ROCA women had lower stress scores over time than SOC women. Given the lack of clinical utility and poor compliance shown with traditional ultrasound and CA125 tests, further investigation is warranted of longitudinal biomarker surveillance for early detection of ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Haque R, Skates SJ, Armstrong MA, et al. Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations. Gynecol Oncol. 2020. PMID: 32145911. doi:10.1016/j.ygyno.2020.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。